Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Age‐related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF‐04523655 for AMD, and SYL040012 and QPI‐1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non‐viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene‐silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non‐viral vectors for siRNA drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Nonviral vectors for gene delivery
Mintzer, M. A., & Simanek, E. E. (2009) · Chemical Reviews · doi:10.1021/cr800409e · Cited by 2,366
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801 , Involved in Apoptosis
Shoshani, T., Faerman, A., Mett, I., Zelin, E., Tenne, T., Gorodin, S., Moshel, Y., Elbaz, S., Budanov, A., Chajut, A., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2283-2293.2002 · Cited by 546
Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration
Golestaneh, N., Chu, Y., Xiao, Y.-Y., Stoleru, G. L., & Theos, A. C. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.453 · Cited by 357
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Corradetti, M. N., Inoki, K., & Guan, K.-L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400557200 · Cited by 237
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189
Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases
Peng, Y., Tang, L., & Zhou, Y. (2017) · Ophthalmic Research · doi:10.1159/000479157 · Cited by 175
Nanotherapy for posterior eye diseases
Kaur, I. P., & Kakkar, S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.031 · Cited by 175
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
Moreno-Montañés, J., Sádaba, B., Ruz, V., Gómez-Guiu, A., Zarranz, J., González, M. V., Pañeda, C., & Jimenez, A. I. (2014) · Molecular Therapy · doi:10.1038/mt.2013.217 · Cited by 76
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
Research works printed but not linked: 111
- 10.1186/s12967-016-1101-8 · DOI · Paper page
- 10.4014/jmb.1711.11025 · doi:10.4014/jmb.1711.11025
- 10.1016/j.jconrel.2012.05.005 · DOI
- 10.1021/acsami.6b16689 · DOI · Paper page
- 10.1016/j.ejpb.2009.04.001 · DOI
- 10.1007/s11095-013-0971-1 · DOI
- 10.1016/S0169-409X(01)00193-4 · DOI · Paper page
- 10.1016/j.ejpb.2005.01.009 · DOI · Paper page
- Barar J., 2009, Ocular drug delivery; impact of in vitro cell culture models, J. Ophthalmic Vis. Res., 4, 238
- 10.1016/j.addr.2006.07.024 · DOI · Paper page
- 10.1007/BF02569055 · DOI · Paper page
- 10.1517/14712598.3.1.45 · DOI · Paper page
- 10.1016/j.ijpharm.2017.07.065 · DOI
- 10.1016/S1773-2247(14)50021-4 · DOI
- 10.4155/tde.12.94 · DOI
- 10.1007/s12668-016-0219-8 · DOI
- 10.1007/s11095-009-0042-9 · DOI
- 10.1016/j.ijpharm.2017.04.010 · DOI
- 10.1007/s13346-016-0335-6 · doi:10.1007/s13346-016-0335-6
- 10.1016/j.addr.2006.07.023 · DOI
- 10.1016/j.addr.2017.07.002 · DOI
- 10.1093/ageing/21.3.168 · doi:10.1093/ageing/21.3.168
- 10.1081/DDC-120002997 · DOI · Paper page
- 10.1371/journal.pone.0026103 · DOI
- 10.1111/jphp.12132 · DOI
- 10.1109/TUFFC.2013.2538 · DOI
- 10.1016/j.ultrasmedbio.2011.07.010 · DOI
- 10.1080/08820530902802161 · DOI
- 10.1016/j.ejps.2012.11.009 · DOI
- 10.1080/02713683.2019.1565890 · DOI · Paper page
- 10.1023/A:1023238530504 · DOI
- 10.1016/j.exer.2019.107711 · DOI · Paper page
- 10.4155/tde.11.20 · DOI
- 10.1136/bjophthalmol-2014-305252 · DOI · Paper page
- 10.2174/156720181101140212165729 · doi:10.2174/156720181101140212165729
- 10.1016/B978-0-8155-2025-2.10007-1 · DOI
- 10.1016/j.addr.2006.07.026 · DOI · Paper page
- 10.1088/0957-4484/20/50/505101 · DOI · Paper page
- 10.1007/s00018-018-2843-7 · DOI
- 10.1016/j.mam.2012.03.009 · DOI · Paper page
- 10.1016/j.arr.2009.01.001 · DOI
- 10.1111/j.1755-3768.2011.02179.x · DOI · Paper page
- 10.1016/j.mam.2012.04.006 · DOI
- 10.3109/09273948.2011.628432 · DOI · Paper page
- 10.1097/IAE.0b013e3181ad2341 · doi:10.1097/iae.0b013e3181ad2341
- 10.1016/S0002-9440(10)64525-7 · DOI · Paper page
- 10.1038/eye.2012.106 · DOI
- 10.1136/bjo.80.4.363 · DOI · Paper page
- 10.1136/bjo.81.2.154 · DOI · Paper page
- 10.4137/OED.S4878 · DOI · Paper page
- Dejneka N.S., 2008, Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes, Mol. Vis., 14, 997
- 10.1097/00006982-200402000-00018 · DOI · Paper page
- Kwak N., 2000, VEGF is major stimulator in model of choroidal neovascularization, Invest. Ophthalmol., 41, 3158
- 10.1038/380439a0 · DOI · Paper page
- 10.1038/sj.gt.3302641 · DOI · Paper page
- 10.1038/nm0603-669 · DOI · Paper page
- 10.5483/BMBRep.2006.39.5.469 · DOI · Paper page
- 10.1016/j.ajo.2010.02.006 · DOI · Paper page
- 10.1167/iovs.04-0052 · DOI · Paper page
- 10.1167/iovs.13-13449 · DOI
- 10.1167/iovs.13-12716 · DOI · Paper page
- 10.2174/1874364101004010052 · DOI · Paper page
- 10.1038/mt.2013.216 · DOI
- Wax M.B., 1987, Distribution and properties of beta adrenergic receptors in human iris/ciliar body, Invest. Ophthalmol. Vis. Sci., 28, 420
- 10.1089/jop.1990.6.143 · doi:10.1089/jop.1990.6.143
- 10.1136/bjo.66.12.788 · doi:10.1136/bjo.66.12.788
- Gonzalez V., 2014, Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma, Investig. Ophthalmol. Vis. Sci., 55, 564
- Gonzalez V., 2016, Results of phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma, Assoc. Res. Vis. Ophthalmol., 57, 3023
- 10.3129/i07-046 · doi:10.3129/i07-046
- 10.2174/157015908784533851 · DOI
- 10.1038/cddis.2011.54 · DOI · Paper page
- 10.1007/s11095-017-2134-2 · DOI · Paper page
- 10.1089/nat.2014.0489 · DOI · Paper page
- 10.1016/j.drudis.2007.11.002 · DOI · Paper page
- 10.1016/j.jconrel.2015.12.012 · DOI · Paper page
- 10.4155/tde.11.20 · DOI
- 10.3390/pharmaceutics11100547 · DOI
- 10.1158/0008-5472.CAN-08-2428 · DOI · Paper page
- 10.1038/sj.gt.3302777 · DOI · Paper page
- 10.1200/JCO.2013.55.0376 · DOI · Paper page
- 10.1016/j.biotechadv.2019.04.012 · DOI · Paper page
- 10.1002/jcph.1480 · DOI · Paper page
- 10.1007/s00415-019-09602-8 · DOI
- 10.1002/mabi.201000302 · DOI
- 10.1021/bc800451j · DOI
- 10.1007/s10118-015-1632-0 · DOI
- 10.1002/mabi.201600051 · DOI
- 10.1039/b900880b · DOI · Paper page
- 10.1016/j.addr.2006.03.007 · DOI · Paper page
- 10.1002/wnan.1233 · DOI
- 10.1023/A:1007552007765 · DOI · Paper page
- 10.1016/j.biomaterials.2012.02.041 · DOI
- 10.1002/jps.21079 · DOI · Paper page
- 10.1039/C1NJ20408D · DOI
- 10.1111/jphp.12104 · DOI · Paper page
- 10.1016/j.ijpharm.2016.07.031 · DOI
- Wu J., 2013, Dendrimers as carriers for siRNA delivery and gene silencing: a review, Sci. World J., 2013, 1, 10.1155/2013/630654 · DOI
- 10.1039/c0jm03030a · DOI
- 10.1016/j.msec.2019.110245 · DOI
- Arranz‐Romera A., 2018, Simultaneous co‐delivery of neuroprotective drugs from multi‐loaded PLGA microspheres for the treatment of glaucoma, J. Control Release, 2019, 26
- 10.1016/j.jconrel.2012.01.043 · DOI · Paper page
- 10.1016/j.drudis.2019.02.001 · DOI · Paper page
- 10.1016/j.jconrel.2007.11.017 · DOI
- 10.1016/j.biomaterials.2010.07.082 · DOI · Paper page
- 10.1016/j.bbrc.2017.05.103 · DOI
- 10.1167/iovs.07-1077 · DOI · Paper page
- 10.1038/sj.gt.3302071 · DOI · Paper page
- 10.1039/C7NR03142D · DOI · Paper page
- 10.1111/jphp.12940 · DOI
- 10.1038/sj.mt.6300324 · DOI · Paper page
- 10.1002/smll.201803239 · DOI
Cited by
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Li, S., Chen, L., & Fu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01992-2 · Cited by 277
Self-citationGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Such viral composition is particularly useful for diseases with large causative genes such as Stargardt disease and Usher syndrome.(22,25,26) Lentiviruses are possibly more immunogenic than AAVs.”
BackgroundNaik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Metadata
- Authors
- Jiang, J., Zhang, X., Tang, Y., Li, S., & Chen, J.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2020-05-08
- Volume
- 35
- Issue
- 1
- Pages
- 4-24
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W3016941443
- Cited by
- 54
- References
- 17
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.